Diyabet Merkezden Takipli Tip 2 Diabetes Mellitus Hastalarında Hipoglisemi Sıklığı ve Hipoglisemi Korkusu

Year 2022, Volume: 16 Issue: 4, 681 - 689, 23.12.2022

Sema Gizem Çalışkan Nazlı Hacıağaoğlu Sabah Tuzun Can Öner Engin Ersin Şimşek Huseyin Cetin

https://doi.org/10.21763/tjfmpc.1023039

Cited By: 1

Abstract

Giriş: Bu çalışma aile hekimliği yönelimli diyabet merkezi (AHYDM) ile hastane yönelimli diyabet merkezi (HYDM)’den takipli tip 2 diabetes mellitus (DM) hastalarında hipoglisemi sıklığı ve ilişkili faktörlerin karşılaştırılmasını amaçlamaktadır. Yöntem: Bu çalışmaya 1 Aralık 2017– 31 Aralık 2019 tarihleri arasında aynı hastaneye bağlı olan iki diyabet merkezine başvuran Tip 2DM hastaları dahil edilmiştir. Çalışmada hastane içerisinde yer alan ve İç Hastalıkları Kliniği tarafından yürütülen DM merkezi HYDM olarak kabul edilirken, hastane kampüsü dışında bulunan, Aile Hekimliği Kliniği tarafından yürütülen DM merkezi ise AHYDM olarak kabul edilmiştir. Her iki merkezdeki açlık plazma glukozu düzeyi en az iki defa 70 mg/dL’nin altında saptanan hastalar vaka grubuna dahil edilmiştir. Ardından, her bir merkezde vaka grubundaki hastalara yaş ve cinsiyet açısından eşleştirilmiş, hipoglisemi atağı bulunmayan Tip 2 DM hastaları kontrol grubu olarak kabul edilmiştir. Ayrıca, Hipoglisemi Korku Ölçeği (HKÖ) iki merkezdeki vaka grubuna da uygulanmıştır. Bulgular: Çalışmaya dahil edilen 240 hastanın 150 (%62,5)’si kadın idi. HYDM’deki tüm hastaların 53(%1,2)’ünde hipoglisemi saptanmışken, AHYDM’den katılan tüm hastaların 27(%0,31)’sinde hipoglisemi tespit edilmiştir. Her iki merkezdeki vaka grubunda DM süresi, insülin kullanım sıklığı ve toplam insülin dozu kontrol grubundan yüksekti (sırasıyla, HYDM için p=0,049, p<0,001, p=0,001; AHYDM için p=0,014, p<0,001, p=0,010). Ayrıca AHYDM'deki vaka grubunda hipoglisemi eğitimi alma sıklığı ve hipoglisemi eğitiminin yeterli olduğu algısı HYDM'ye göre daha yüksekti (sırasıyla p=0,029 ve p=0,046). İki merkezde de HKÖ’de fark bulunmamıştır (p>0,05). Sonuç: DM hastalarında, özellikle insülin kullanan ve T2DM süresi uzun olan hastalarda hipoglisemi açısından dikkatli değerlendirilmesi gereklidir. Ayrıca hastaların aile hekimleri tarafından hipoglisemi ile ilgili eğitilmesi hipoglisemi görülme sıklığını azaltabilir.

Keywords

Tip 2 diabetes mellitus, hipoglisemi, açlık hipoglisemisi

Supporting Institution

yok

The Frequency of Hypoglycemia and Hypoglycemia Fear in Type 2 Diabetes Mellitus Patients with Followed-up from Diabetes Center

Abstract

Introduction: This study aimed to compare the frequency of hypoglycemia and related factors in type 2 diabetes mellitus DM) patients followed up by a family practice-oriented diabetes center (FPODC) and hospital-oriented diabetes center (HODC). Method: Type 2 DM patients who applied to two diabetes centers affiliated with the same hospital between 1 December 2017-31 December 2019 were included in the study. The DM center located in the hospital and managed by the Internal Medicine Clinic was accepted as HODC, while the DM center located outside the hospital campus and manage by the Family Practice Clinic was accepted as FOPDC. Patients with fasting plasma glucose levels determined to be below 70 mg/dL at least twice in both centers were included in the case group. Subsequently, patients in the case group in each center were matched in terms of age and gender, and T2DM patients without hypoglycemia were accepted as the control group. Besides, the Hypoglycemia Fear Scale (HFS) was applied to the case group patients in both centres. Results: Of the 240 patients included in the study, 150 (62.5%) were female. While hypoglycemia was detected in 53 (1.2%) of patients in HODM, hypoglycemia was detected in 27 (0.31%) patients participating in FOPDC. The duration of DM, frequency of insulin use and insulin dose were higher in both centers cases than in the control group (p=0,049, p<0,001, p=0,001 for HODC; p=0,014, p<0,001, p=0,010 for FOPDC, respectively). Moreover, the frequency of hypoglycemia education and the perception that hypoglycemia education is sufficient in the case group in the FOPDC were higher than in HODC (p=0.029 and p=0.046, respectively). There was no difference in HFS scores between both centres (p>0,05). Conclusion: Evaluation of hypoglycemia is necessary for type2 2DM patients who use insulin and have a long duration of DM. In addition, educating patients about hypoglycemia by their family physicians may reduce the frequency of hypoglycemia.

Keywords

type 2 diabetes mellitus, hypoglycemia, fasting hypoglycemia

References

• 1. Samya V, Shriraam V, Jasmine A, Akila GV, AnithaRani M, Durai V, et al. Prevalence of hypoglycemia among patients with type 2 diabetes mellitus in a rural health center in South India. J Prim Care Community Health 2019;10:2150132719880638.
• 2. Kalra S, Mukherjee JJ, Venkataraman S, Bantwal G, Shaikh S, Saboo B, et al. Hypoglycemia: The neglected complication. Indian J Endocrinol Metab 2013;17(5):819–34.
• 3. Bain SC, Cummings MH, McKay GA. Multidisciplinary Approachto Management and Care of Patients with Type 2 Diabetes Mellitus. EMJ Diabet 2019;7(1):73-81.
• 4. Shrivastav M, Gibson Jr W, Rajendra Shrivastav R, Katie Elzea, Cyrus Khambatta, Rohan Sonawane, et al. Type 2 Diabetes Management in Primary Care: The Role of Retrospective, Professional Continuous Glucose Monitoring. Diabetes Spectr 2018;31(3):279–87.
• 5. Lam AYR, Xin X, Tan WB, Gardner DSL, Goh SY. Psychometric validation of the hypoglycemia FearSurvey-II (HFS-II) in Singapore. BMJ Open Diabetes Res Care 2017;5(1):e000329.
• 6. Erol O, Enc N. Hypoglycemia fear and self-efficacy of Turkish patients receiving insulin therapy. Asian Nurs Res (Korean Soc Nurs Sci) 2011;5(4):222-8.
• 7. Saito T, Ohmura H, Nojiri S, Daida H. Impact of Sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: amulti-center retrospective observational cohort study. Journal Pharm Health Care Sci 2020;6:1-8.
• 8. Rodriguez-Gutierrez R, Salcido-Montenegro A, Singh-Ospina NM, Maraka S, Iñiguez-Ariza N, Spencer-Bonilla G, et al. Documentation of hypoglycemia assessment among adults with diabetes during clinical encounters in primary care and endocrinology practices. Endocrine 2020;67(3):552-60.
• 9. Van Meijel LA, De Vegt F, Abbink EJ, Rutters F, Schram MT, Van Der Klauw MM, et al. high prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with ınsulin-treated type 2 diabetes: the Dutch diabetes pearl cohort. BMJ Open Diabetes Research and Care 2020;8(1):e000935.
• 10. Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. Journal of Diabetes&Metabolic Disorders 2012;11(1):17.
• 11. Giorda CB, Ozzello A, Gentile S, Aglialoro A, Chiambretti A, Baccetti F, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the Hypos-1 study. Acta Diabetol 2015;52(5):845-53.
• 12. Tschöpe D, Bramlage P, Binz C, Krekler M, Deeg E, Gitt AK. Incidence and predictors of hypoglycaemia in type 2 diabetes–an analysis of the prospective diaregis registry. BMC Endocr Disord 2012;12(1):23.
• 13. Genç B. İnsülin kullanan diyabetli hastalarda hipoglisemi sıklığı şiddeti etkileyen faktörler. Ankara, 2020. (Yüksek Lisans Tezi). p.35.
• 14. Jensen MH, Hejlesen O, Vestergaard P. Association of insulin regimens with severe hypoglycaemia in patients with type 1 diabetes: a Danish case–control study. Br J Clin Pharmacol2020;86(8):1560-6.
• 15. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014;63(5):1738-47.
• 16. Hsieh YC, Liao YC, Li CH, Lin JC, Weng CJ, Lin CC, et al. Hypoglycaemic episodes increase the risk of ventricular arrhythmia and sudden cardiac arrest in patients with type 2 diabetes—a nationwide cohort study. DiabetesMetabResRev 2020;36(2):E3226.
• 17. Simeone JC, Quilliam BJ. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large us administrative claims database. AnnPharmacother 2012;46(2):157-68.
• 18. Giorda CB, Ozzello A, Gentile S, Corsi A, Iannarelli R, Baccetti F. Incidence and correlates of hypoglycemia in type 2 diabetes. The Hypos-1 study. J Diabetes Metab 2014;5(3):1-8.
• 19. Rathmann W, Charbonnel B, Gomes MB, Hammar N, Khunti K, Kosiborod M, et al. Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: the DISCOVER study. Diabetes Res Clin Pract 2020;165:108250.
• 20. Saulnier PJ, Briet C, Gand E, Chaillous L, Dubois S, Bonnet F, et al. No association between fear of hypoglycemia and blood glucose variability in type 1 diabetes: the cross-sectional VARDIA study. Journal Diabetes Complications 2019;33(8):554-60.
• 21. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008;10 Suppl 1:16-24.
• 22. Pagkalos E, Thanopoulou A, Sampanis C, Bousboulas S, Melidonis A, Tentolouris N, et al. The real-life effectiveness and care patterns of type 2 diabetes management in Greece. Exp Clin Endocrinol Diabetes 2018;126(01):53-60.
• 23. Shi L, Shao H, Zhao Y, Thomas NA. Is hypoglycemia fear independently associated with health-related quality of life?. Health Qual Life Outcomes 2014;12(1):167.
• 24. Simon D, De Pablos-Velasco P, Parhofer KG, Gönder-Frederick L, Lomon ID, Vandenberghe H, et al. Hypoglycaemic Episodes in Patients with type 2 diabetes–risk factors and associations with patient-reported outcomes: the PANORAMA Study. Diabetes Metab 2015;41(6):470-9.
• 25. Polonsky WH, Fisher L, Hessler D. The impact of non-severe hypoglycemia on quality of life in patients with type 2 diabetes. J Diabetes Complications 2018;32(4):373-8.